AlphAIalphai — Financial news for AI agents
Stock TitanMAR 24 min read$HROW

Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook

Harrow, Inc. reported strong financial results for Q4 and full-year 2025, with revenue increasing 36% to $272.3 million for the year. The company provided 2026 guidance, expecting revenue between $350 million and $365 million and Adjusted EBITDA of $80 million to $100 million, driven by the expanding sales teams for key ophthalmic brands VEVYE and TRIESENCE, and the strategic repositioning of IHEEZO. Harrow also highlighted significant progress in its development pipeline, including G-MELT and YOCHIL, reinforcing confidence in its long-term growth strategy.

Original reporting
Stock Titan
Published Mar 2, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 2, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$HROW
Bullish
high confidence
Mentioned
$HROW
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$HROWBullishMed
01

Why it matters

Positive outlook may boost investor confidence, but caution is advised due to sector volatility.

02

Market read

The positive guidance and pipeline progress support a bullish outlook for Harrow, with potential sector-wide benefits.

03

What to watch

Potential delays in pipeline development, regulatory hurdles, or macroeconomic headwinds could impact performance.

Timing: short to medium term (next 3-6 months)

Background

Harrow's recent earnings and guidance reflect a strategic focus on expanding sales and pipeline development in ophthalmic treatments.

Company-level read

Ticker impact

$HROWBullishHigh confidence
Context

Primary focus due to recent earnings report and guidance.

Expected impact

Moderate upward movement in the near term, with potential for continued growth if guidance is met or exceeded.

Evidence & confidence

Strong revenue growth, positive guidance, and pipeline advancements suggest sustainable growth trajectory. The bullish sentiment from the market sentiment score supports this outlook.

Market effects

Sector

Positive sentiment for the life sciences and healthcare sectors, especially ophthalmic and biotech companies.

Regional

Limited regional impact; primarily US-focused due to company's geographic operations.

Global

Moderate; reflects broader healthcare innovation trends but limited direct global influence.

Counterpoint

What could challenge this read

The strong guidance may be overly optimistic; actual results could fall short due to market or execution risks.

Key entities

  • Company
    Harrow, Inc.

    A healthcare company specializing in ophthalmic treatments.

  • Product
    VEVYE

    A key ophthalmic product contributing to revenue growth.

  • Product
    TRIESENCE

    Another flagship ophthalmic product with growth potential.

  • Product
    IHEEZO

    Strategically repositioned ophthalmic drug.

  • Pipeline Candidate
    G-MELT

    Development pipeline candidate indicating future growth.

Read at source← All news

Related articles

AUG 13
$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

yahoo.com6 min
AUG 10
$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits

SEC EDGAR 8-K7 min
JUL 1
$HROWMed

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

manilatimes.net4 min
AUG 13
$RIOTHighAI 9/10

Anthropic Just Paid $9 Billion to Rent a Bitcoin Miner's Power Grid

Anthropic, the developer of Claude, agreed with Riot Platforms to lease 191 MW of computing capacity at Riot’s Rockdale, Texas site for $9.1 billion over 20 years through June 2048, with two five-year extension options that could raise total value to $16.1 billion, according to Riot’s regulatory filing. RIOT shares rose over 25% after the disclosure.

memeburn.com6 min
AUG 13
$BAMed

US jury awards $29 mn damages to Boeing 737 MAX victim's family

A Chicago jury awarded $29 million in damages to the family of Naoise Connolly Ryan, widow of UN engineer Michael Ryan, who died in the 2019 Boeing 737 MAX crash. The civil suit was filed against Boeing. The article notes Boeing apologized and said anti-stall software was implicated. It cites another $49.5 million award in May.

bssnews.net2 min